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Abstract
Background: Design of tumour specific immunotherapies using the patients’ own dendritic cells (DC) is a fast
advancing scientific field. The functional qualities of the DC generated in vitro are critical, and today’s gold
standard for maturation is a cytokine cocktail consisting of IL-1b, IL-6, TNF-a and PGE2 generating cells lacking IL-
12p70 production. OK432 is an immunotherapeutic agent derived from killed Streptococcus pyogenes that has been
used clinically to treat malignant and benign neoplasms for decades.
Methods: In this study, we analysed the effects of OK432 on DC maturation, DC migration, cytokine and
chemokine secretion as well as T-cell stimulatory capacity, and compared it to the cytokine cocktail alone and
combinations of OK432 with the cytokine cocktail.
Results: OK432 induced a marked up-regulation of CD40 on the cell surface as well as a strong inflammatory
response from the DC with significantly more secretion of 19 different cytokines and chemokines compared to the
cytokine cocktail. Interestingly, secretion of IL-15 and IL-12p70 was detected at high concentrations after
maturation of DC with OK432. However, the OK432 treated DC did not migrate as well as DC treated with cytokine
cocktail in a transwell migration assay. During allogeneic T-cell stimulation OK432 treated DC induced proliferation
of over 50 percent of CD4 and 30 percent of CD8 T-cells for more than two cell divisions, whereas cytokine
cocktail treated DC induced proliferation of 12 and 11 percent of CD4 and CD8 T-cells, respectively.
Conclusions: The clinically approved compound OK432 has interesting properties that warrants its use in DC
immunotherapy and should be considered as a potential immunomodulating agent in cancer immunotherapy.
Background
Dendritic cells (DC) are a pivotal part of the immune
system, bridging the innate and adaptive immune
response. After receiving maturation stimuli such as
inflammatory cytokines, direct T-cell stimulation or
recognition of pathogen-associated molecular patterns
(PAMP), the DC up-regulate the surface expression of
major histocompatibility complex (MHC) class II as well
as a number of co-stimulatory markers [1]. During
maturation the DC shift role from antigen up-take to
antigen presentation on MHC and migrate to secondary
lymphoid organs where the DC stimulate T-cells with
the appropriate T-cell receptor. Much work has been
carried out to utilise the unique features of DC in clini-
cal applications as ex vivo generation of DC has become
standard practice [2,3]. Especially, their role in the treat-
ment of malignant neoplasms is one of the areas in
which DC show great promise, due to their unique
capacity to activate naïve T-cells [4-8].
Immunotherapies with the aid of DC have been shown
to be a safe and non-reactogenic way to improve the
immune response towards cancer [4-8]. However, it is
clear that the immune responses achieved so far have
not reached its theoretical potential and DC based
therapies have not yet become a standard care of treat-
ment [9]. A recent meta-study found that around 30%
of 338 melanoma patients treated with matured DC had
either complete response (CR), partial response (PR) or
stable disease (SD) [10]. Of the immunological para-
meters, particularly the induction of antigen specific
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T-cells was found to be predictive of a positive outcome
(CR, PR and SD).
The ex vivo protocol published by Jonuleit et al. has
been hailed as the ‘gold standard’ in DC maturation
[11]. The combination of interleukin (IL)-1b, IL-6,
tumour necrosis factor (TNF)-a and prostaglandin E2
(PGE2) has enabled researchers to produce ex vivo
matured good manufacturing practice (GMP)-grade DC
in large numbers and good viability. This protocol, how-
ever, has its deficiencies as the resulting immune
response is not optimal for therapeutic cancer vaccina-
tion, particularly with its lack of IL-12p70 production
[12]. To correct these deficiencies, a number of DC
maturation protocols and a range of DC stimuli has
been tested for use in cancer immunotherapy [13].
The most critical aspect of DC in conjunction with
clinical therapies is the T-cell stimulating capacity of the
DC. The DC must be functionally mature in order to
induce T-cell activation and not T-cell anergy. Further-
more, the DC must have the ability to migrate to the
secondary lymphoid organs to present antigens and
induce the effector arm of the immune system. Alterna-
tively, the DC must be able to attract the T-cells to the
site of DC injection by secreting signal substances like
CCL21 and subsequently induce a T-cell response [14].
In search of better maturation stimuli, we investigated
the low-virulence strain of penicillin-killed Streptococcus
pyogenes (OK432) first described by Okamoto and collea-
gues [15]. OK432 is available as a licensed drug (trade
name, Picibanil) that has already been proven to have little
side-effects and has been used efficiently to treat a variety
of tumours [16,17]. A meta-study showed significantly bet-
ter survival with chemotherapy combined with OK432
treatment [18]. The effect of OK432 in cancer patients is
not adequately explained, but in vitro cultures of OK432
and DC induced the production of inflammatory cytokines
[19] and a Th1 like type of response [20,21]. Sato et al.
[22] did analyse the effect of OK432 on cells from 4 cancer
patients with different tumours. Moreover, a small number
of patients with glioma enrolled in a phase I/II trial
received OK432 treated dendritic cells with promising
results [23]. However, additional information is needed to
conclude about the effect of OK432 on DC. This is espe-
cially important as cancer patients have an inflammatory
tumour micro-environment that negatively affects the
immune system that also vary between cancer types and
progression [Reviewed in [24]].
We used OK432 as a maturation stimulus for DC,
both alone in different concentrations or in combination
with the Jonuleit cytokine cocktail and compared it to
the cytokine cocktail alone in order to understand the
effect of OK432 on DC and its possible use in a clinical
setting. We found increased secretion of a number of
chemokines and cytokines that would result in a local
inflammation stronger than that seen after maturation
with the cytokine cocktail. Furthermore, the important
cytokines IL-15 and IL-12p70 were detected after
maturation of DC with OK432, as well as an up-regu-
lated expression of CD40 and a marked increase in
T-cell stimulatory capacity. The clinically approved
OK432 has interesting properties and should be consid-
ered for further DC cancer immunotherapy.
Methods
DC generation
DC were generated from monocytes isolated from buffy
coat preparations from healthy blood donors (Blood
Bank, Haukeland University Hospital, Bergen, Norway)
as described [25]. Briefly, peripheral blood mononuclear
cells were separated by a density gradient centrifugation
and the monocytes were then isolated by plastic adher-
ence. Some experiments were performed with negatively
isolated monocytes from buffy coat blood using the
Dynabeads® Untouched™ Human Monocytes (Invitrogen,
Carlsbad, CA) following the manufacturer’s instructions.
The monocytes were cultured with IL-4 (20 ng/ml;
Immunotools, Friesoythe; Germany) and GM-CSF (100
ng/ml; Immunotools, Friesoythe; Germany) in RP10
medium (RPMI 1640 (Cambrex Bioscience, Verviers,
Belgium) with 10% FCS (PAA, Pasching, Austria);
100 units/ml penicillin and 100 μg/ml streptomycin
(Sigma-Aldrich, St. Louis, MO)) for 5-6 days to generate
immature DC. Cytokines were replenished every 2-3
days. The maturation of dendritic cells was performed
for 24 hours with a mix of stimuli (IL-1b, 10 ng/ml; IL-6,
1000 U/ml; TNF-a 10 ng/ml (all from Immunotools,
Friesoythe; Germany) and PGE2, 1 μg/ml (Sigma-Aldrich,
St. Louis, MO) or with OK432 (Picibanil, Chugai Phar-
maceutical Co. Ltd, Tokyo, Japan), or a combination of
stimuli. The dose of OK432 was given in Klinische
Einheit (KE), where 1 KE equals approximately 0.1 mg.
Two concentrations of OK432 were tested, 0.1 and 0.01 KE.
Flowcytometry
Immunostaining was performed as described previously
[25]. Briefly, cells were incubated with a titrated amount
of antibodies for 10 minutes at room temperature before
the cells were washed and immediately analysed on a
FACSCanto I cytometer (BD Biosciences, Heidelberg,
Germany). All subsequent analyses and gating were done
with the FlowJo software (Tree Star, Ashland, OR). One
percent false-positive events were accepted in the isotype
controls. The antibodies used were CD1-PE (NA1/34-
HLK), CD8-PE (LT8), CD14-FITC (UCHM1), HLA-
DR-APC (HL-39), CD38-Alexa Fluor 647(AT13/5),
CD86-FITC (BU63), CD83-PE (HB15e), CD80-APC
(MEM-233), CD40-FITC (LOB7/6), all from AbD Serotec
(Düsseldorf, Germany); CCR7-PE, (150503) from R&D
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Systems (Minneapolis, MN); CD4-APC (MEM-241), CD16-
PE (LNK16), CD56-APC (MEM-188) from ImmunoTools,
Friesoythe, Germany; and CD3-PerCP-Cy5.5 (UCHT1)
from BD Biosciences (San Jose, CA).
Mixed lymphocyte reaction (MLR)
Allogeneic peripheral blood mononuclear cells (PBMC)
depleted for monocytes were thawed and allowed to rest
for 24 hours before being labelled with CFDA-SE (Invi-
trogen, Carlsbad, CA) according to the manufacturer’s
instructions. Two hundred thousand CFDA-SE labelled
lymphocytes were then co-cultured with twenty or forty
thousand extensively washed, irradiated, allogeneic
matured DC. At the start of the co-culture 50 U/ml of
IL-2 and 10 ng/ml of IL-7 (both Immunotools, Frie-
soythe; Germany) were added to ensure CD4 and CD8
T-cell survival. After 5 days the cells were harvested,
stained for CD4 and CD8 for T-cell and CD16 and CD56
for NK cell analysis using a FACS Canto I flowcytometer.
The gating strategy included exclusion of cell doublets.
Chemotaxis assay
After maturation, the DC were harvested and washed
extensively. 50 000 live cells were added to the upper
chamber of an 8 μm transwell 96-well plate (Corning
Lifescience, Lowell, MA) and left to migrate towards
CCL19 (100 ng/ml, Immunotools, Friesoythe; Germany)
for 16 hours at 37°C, 5% CO2 humidified atmosphere.
The migrated cells were mixed with a known concentra-
tion of beads, counted with a FACSCanto I cytometer,
and presented as a percentage of the total number of
cells added to the upper well.
Cytokine determination
To determine the concentration of cytokines and chemo-
kines from the conditioned medium after maturation of
the DC, aliquots of the supernatants were stored at -20°C.
All samples were tested simultaneously in a 25-plex Lumi-
nex assay cytokine and chemokine kit (Invitrogen, Carls-
bad, CA) and run on a Luminex 100 System (Luminex
Corporation, Austin, TX) according to the manufacturer’s
instructions. A sandwich ELISA was run separately for
IL-12p70 (BioLegend, San Diego, CA), TGF-b1 (R&D Sys-
tems, Minneapolis, MN) and IL-23 (eBioscience, San
Diego, CA) according to the manufacturer’s instructions.
Statistical analyses
To compare the effect of the stimuli on the DC, group
wise analyses were performed with Mann-Whitney non-
parametric test. Significance was set at p < 0.05. For the
correlation examination, a bivariate analysis shown by
the Spearman coefficient (r) and the two-tailed test of
significance was calculated. All statistical calculation was
done with SPSS 15 (SPSS, Chicago, IL) and the
correlation heat maps were generated with the iVici pro-
gram http://michnick.bcm.umontreal.ca/ivici/index.html.
Results
OK432 treatment of DC results in maturation and induces
higher levels of CD40 compared to the cytokine cocktail
In order to elucidate if the apparent effect seen by the
clinical use of OK432 in treatment of tumours is
mediated via DC, we first generated monocyte derived
immature DC. After a 24-hour maturation stimulus with
either 0.1 KE OK432 or cytokine cocktail, both popula-
tions had a clear (p < 0.05) up-regulation on the level of
HLA-DR and CD86 compared to the immature DC
(Figure 1). A reduced dose of 0.01 KE OK432 also
1. Imm
2. Cyto
4. 0.1KE OK432+Cyto
3. 0.1KE OK432
5. 0.01KE OK432
6. 0.01KE OK432+Cyto
Figure 1 DC stimulated with OK432 are phenotypically mature
with high expression of CD40. The number of percent positive
cells is shown for all surface markers, except CD40, which is
displayed with the median fluorescence intensity (MFI) as all groups
of DC showed more than 97 percent cells positive for CD40. The
number of donors is six for all markers except CD38 where the
number of donors is 3 for key 4-6. The distribution is shown by the
max/min as well as the 25, 50 and 75 quartiles. Figure key: 1)
immature DC (Imm), 2) cytokine cocktail treated DC (Cyto), 3) 0.1KE
OK432 treated DC (0.1KE OK432), 4) 0.1 KE OK432 + cytokine
cocktail treated DC (0.1KE OK432+Cyto), 5) 0.01 KE OK432 treated
DC (0.01KE OK432) and 6) 0.01KE OK432 + cytokine cocktail treated
DC (0.01KE OK432+Cyto).
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induced a statistically significant, but lower, increase of
HLA-DR and CD86 compared to immature DC.
Maturation of DC with the cytokine cocktail led to
higher levels of the co-stimulatory markers CD80 and
CD86 (p < 0.02) and activation marker CD83 (p < 0.05)
on the cell surface than OK432 treated DC. The use of
cytokine cocktail and OK432 led to a phenotype resem-
bling that of cytokine cocktail alone. The level of CD40
together with the other co-stimulatory molecules is
important for an adequate stimulation of T-cells [26].
OK432 induced a 75 percent higher median fluores-
cence intensity (MFI) of CD40 on the surface of the DC
compared to cytokine cocktail alone (p < 0.01) or cyto-
kine cocktail and OK432. The MFI values for all mar-
kers are given in additional file 1. The level of CCR7, a
marker important for migration, was also investigated.
However, the MFI was only modestly increased after
OK432 treatment and the difference was not statistically
significant.
CD38 is a cyclic ADP ribose hydroxylase involved in
the regulation of intracellular Ca2+ [27]. Its surface
expression on DC has been reported to have a range of
different functions in migration, survival, IL-12p70 pro-
duction [28] and support Th1 skewing of the immune
response [29]. OK432 up-regulated CD38 on mature DC
(p < 0.05), in contrast to the cytokine cocktail, which
reduced CD38 expression compared to immature DC
(not statistically significant).
Cytokine cocktail induces the highest level of chemotaxis
One possible reason for the promising clinical effects of
OK432 might be an improved ability of DC to migrate
to sites of inflammation. The differentially matured DC
were therefore tested in a transwell migration assay to
investigate if the different maturation stimuli resulted in
changes in DC mobility towards CCR7 ligand CCL19
(Figure 2). This chemokine has been shown to be at
least one order of magnitude more potent than CCL21
for directing DC chemotaxis in a murine model [30].
DC treated with the cytokine cocktail migrated best,
followed by a combination of cocktail and 0.01KE
OK432, which was slightly better in migration than the
cytokine cocktail and 0.1KE OK432. Of the DC that
received only OK432, the group that received 0.01KE
OK432 migrated to about the same extent as the DC
matured with 0.1KE OK432. Unlike previous reports,
the level of CD38 as percent positive cells or as MFI
(Table 1) was not linked to better performance in the
chemotaxis assay [31].
OK432 elicits a pro-inflammatory cytokine and chemokine
profile
Production and release into the medium of 28 cytokines
and chemokines was analysed by a multiplex luminex
assay and sandwich ELISA (Figure 3). OK432 treatment
induced the secretion of a range of pro-inflammatory
cytokines that were not detected after maturation with
the cytokine cocktail. IL-1RA, -2R, -6, -7, 10, -12p40,
-12p70, -15, -17, -23, IFN-a, and IFN-g and all the
chemokines tested (CCL3/MIP1a, CCL4/MIP1b,
CXCL10/IP10, CXCL9/MIG, CCL11/Eotaxin, CCL5/
RANTES and CCL2/MCP1) were significantly (p < 0.05)
up-regulated after 24 hour stimulation with 0.1 KE
Figure 2 DC maturated with OK432 show less migration
towards CCL19 compared to cytokine cocktail treated DC. After
24 hours stimulation with the indicated stimuli, the migratory
capacity of the DC populations towards CCL19 was analysed in a
transwell migration assay for 16 h. The chemotaxis is presented as
the percentage of cells that migrated to the bottom well relative to
the input number of DC in the upper well. The number of donors is
six. The distribution is shown by the max/min as well as the 25, 50
and 75 quartiles. See figure 1 for figure key.
Table 1 Parameters significantly associated with DC
chemotaxis ex vivo
Spearman coefficient, r P-value
IL-1b -0.442 0.045
IL-8 0.472 0.023
CXCL9 -0.483 0.020
HLA-DRa 0.365 0.044
HLA-DR b 0.400 0.026
CD86a 0.788 0.000001
CD86 b 0.641 0.0001
CD83a 0.763 0.000001
CD83 b 0.412 0.021
a measured as percent positive cells; b measured as median fluorescence
intensity
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OK432 compared to the cytokine cocktail. TNF-a was
borderline significantly higher (p = 0.056) in superna-
tants from cells matured with OK432, even though
TNF-a was a part of the cytokine maturation cocktail
and not added to the cultures receiving OK432. The
reduced concentration of 0.01KE OK432 resulted in
from a 2-fold increase to almost no detection of the
secreted cytokines and chemokines compared to the
cytokine cocktail, therefore a reduced concentration of
OK432 did not achieve satisfying maturation.
In general, using combinations of the cytokine cocktail
and OK432 resulted in a similar, but lower, level of
cytokines and chemokines as compared to the cytokine
cocktail alone. With regard to IL-12p70 and IL-15, the
production was lost or greatly reduced (> 95 percent)
when both stimuli were combined and thus the combi-
nation of cytokine cocktail and OK432 was of lesser
interest. To exclude the possibility of inducing a regula-
tory T-cell response, the amount of TGF-b1 was mea-
sured and found not to be increased after OK432
treatment (data not shown).
Surface expression of maturation markers predict
elevated chemotaxis
In order to understand the differences in maturation
induced by the stimuli tested, a correlation analysis was
Figure 3 OK432 stimulated DC secrete higher quantities of cytokines and chemokines compared to cytokine cocktail treated DC. The
DC were stimulated for 24 hours and the amount of cytokines/chemokines secreted were analysed using a 25-plex bead assay and a sandwich
ELISA for IL-12p70, IL-23 and TGF-b1. Only cytokines and chemokines with statistically (group wise analyses with Mann-Whitney) different
concentrations between DC stimulated with cytokine cocktail and 0.1 KE OK432 are shown, with the exception of IL-8. No significant difference
was found for IL-1b, IL-2, IL-5, IL-13, TGF-b1 and TNF-a. GM-CSF and IL-4 were part of the added cytokines and therefore not considered in the
analysis. The concentrations are given in pg/ml. See figure 1 for figure key.
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undertaken to elucidate which of the parameters were
regulated in a similar manner. The goal was two-fold;
firstly to investigate which parameter predicted good
migratory capacity for all matured DC and secondly; to
envisage the differences between OK432 and the cytokine
cocktail in general. The parameters included in the analy-
sis were the percentage of positive cells for the surface
markers tested and the MFI of CD40, the concentration
of 27 chemokines and cytokines in conditioned medium
from the matured DC and the percentage of DC that
migrated towards CCL19. The analysis revealed that IL-8
production and the surface expression of HLA-DR, CD86
and CD83 were positively correlated with increased che-
motaxis ability, shown by the Spearman coefficient (r)
(Table 1). CXCL9 and IL-1b were significantly negatively
correlated with chemotaxis and the same trend was seen
for CD38 but without statistical significance (r = -0.418,
p = 0.075). CCR7 expressed as percent positive cells
was only weakly associated with chemotaxis (r = 0.185,
p = 0.320), this was also true when testing CCR7 MFI
(r = 0.240, p = 0.194). To relate the different stimuli to
all the parameters tested, a correlation analysis was per-
formed and the correlation matrixes for the cytokine
cocktail and OK432 are shown in a heat map (Figure 4)
to allow an appreciation of the differences the two
maturation stimuli have on the parameters tested. The
figure clearly demonstrates that the cytokine cocktail and
OK432 have distinctly effects on both the surface mar-
kers and secreted cytokines and chemokines.
Dendritic cells matured with OK432 are best in allogeneic
T-cell stimulation
As OK432 induced high surface expression of CD40 as
well as high levels of cytokines and chemokines, we next
tested if this increased inflammatory milieu surrounding
matured DC would be of functional consequence in
T-cell induction. Combinations of OK432 and cytokine
cocktail or reduced concentrations of OK432 were not
tested in MLR as they did not elicit adequate maturation
levels, chemotaxis and reduced level of secreted inflam-
matory cytokines and chemokines by the DC. First, any
direct stimulation effect of the T-cells by residual
OK432 was ruled out as culturing T cells alone with 0.1
KE OK432 resulted in no T-cell proliferation (Figure
5A). The total NK cell compartment (CD3-CD16+CD56
+/-CFSE+) showed no remarkable differences between
the DC stimuli (Figure 5B).
Matured DC were co-cultured with allogeneic T-cells
in a PBMC culture depleted for monocytes and the level
of induced proliferation was measured by CFSE-dilution
(Figure 5C, D). Immature DC induced a low level of pro-
liferation, with around 10 percent of CD4 and 6 percent
CD8 positive lymphocytes having undergone more than
2 divisions after five days of co-culture. In comparison,
using cytokine cocktail treated DC around 23 percent of
CD4 and 28 percent of CD8 positive T-cells had under-
gone more than 2 divisions. OK432 treated DC induced
extensive T-cell proliferation with more than 50 percent
of CD4 and more than 40 percent of CD8 positive cells
having undergone more than two cell divisions; most had
undergone five or more cell divisions. Importantly,
OK432 treated DC stimulated 2-3 fold more CD4 posi-
tive T-cells in later generations (generation 4-7) and
about 2-fold more CD8 positive T-cells in later genera-
tions than cytokine cocktail treated DC (Figure 5E, F).
Discussion
The use of OK432 in different clinical applications has
resulted in positive clinical outcomes over a period of
several decades [15-17,32]. The immunomodulating
mechanism behind OK432 has not yet been conclusively
determined, but a general boost of the immune system
seems evident. OK432 and other microbial products are
sensed by PAMPs which results in an immune activa-
tion. This primes the immune system, as demonstrated
by the effect of intralesional OK432 injections into lym-
phangioma [17]. These clinical experiences led us to
investigate if OK432 might also be of use in other forms
of immunomodulation. Although other researchers have
worked with OK432 and DC, a combination of OK432
and the cytokine cocktail has not been thoroughly inves-
tigated after DC stimulation. The effects of OK432
dosage and the combination with cytokine cocktail on
DC maturation and the full range of chemokines and
cytokines that we present have not been reported before.
Elicitation of an anti-tumour immune response is the
aim of cancer immunotherapy and for all DC based
vaccine approaches the immune response relies heavily
on the immune-stimulatory capacity of the DC popula-
tion being used. This quality is above all dependent of
the choice of maturation stimuli, which in the clinical
protocols is often a cocktail of cytokines, first described
by Jonuleit et al. [11]. One challenging aspect with this
protocol is the addition of PGE2, which is thought to be
necessary to ensure DC survival and migration, and also
induce expression of OX40L [33]. However, the produc-
tion of IL-12p70, which is crucial for initiation of the
required Th1 type of response and the induction of high
quality CTL, is lost by the use of the cytokine cocktail
as also we have demonstrated, and this is due to the
addition of PGE2 [34,35]. PGE2 treated DC have also
been found to attract T-regulatory cells, which would be
negative for induction of an immune response [36].
Thus, Palucka et al. summarised their work by empha-
sising that the next generation of DC immunotherapy
should elicit high concentrations of IL-12p70 and IL-15,
in addition to surface expression of co-stimulatory
molecules on the DC [37].
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Stimulation with OK432 increased the secretion of
nearly all cytokines and chemokines tested, suggestive of
an increased local inflammation when used in immu-
notherapy. This included also IL-15 and IL-12p70 which
have been found to be important for the proliferation of
NK cells and IFN-g production by DC, and both aspects
are of importance in generating a potent Th1 type of
immune response [38]. Endogenous IL-15 production at
the same time as antigen priming has been shown to be
central to the priming and longevity of the CTL response
[39,40]. From our data it is also clear that no synergistic
effects could be detected as combinations of the cytokine
cocktail and OK432 resulted in a greatly reduced
IL-12p70 and IL-15 production. We cannot, however,
rule out that a sequential stimulation might have changed
this cytokine profile, as demonstrated with the TLR3 ago-
nist poly I:C and the cytokine cocktail [41] and this might
be analysed in future studies. In a murine study, IL-7 was
found to boost vaccine-induced antitumour immunity by
increasing both T-cell effector function and the NK cell
numbers [42], but only small differences were detected in
NK cell numbers after co-culture of lymphocytes and DC
in our experiments. From the presented cytokine and
chemokine data it seems evident that the inflammatory
milieu surrounding DC treated with OK432 was elevated
and in the direction of a Th1 response. Also in wash-out
cultures of OK432 treated DC, the IL-12p70 production
was sustained at a low level (~300 pg/ml) for at least 48
hours without any stimuli (data not shown). Although
that is considerably lower than after 24 hours with
OK432 stimulation, it is still remarkable that the DC are
able to secrete IL-12p70 after the stimulus is lifted. As
OK432 has a good safety profile, it could possibly also be
used systemically after DC infusion in patients to prolong
and sustain the proinflammatory response. A distinct set
of immune responses was detected between OK432 and
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the cytokine cocktail from the correlation on the mea-
sured parameters. This illustrated clearly that OK432 and
the cytokine cocktail affected the different parameters
measured very differently with OK432 up-regulating
more cytokines, chemokines and co-receptors.
When the different matured DC populations were
tested in a mixed lymphocyte reaction, the inflammatory
response induced by OK432 on DC was sustained in the
absence of further stimuli. The secreted cytokines,
chemokines and co-stimulatory molecules induced a
high proliferation of both CD4 and CD8 T-cells. This is
an indication that OK432 induced the DC to become
more supportive of T-cell proliferation than the cytokine
cocktail demonstrating the potential to stimulate the cell
mediated immune response. Importantly, the OK432
stimulated DC were particularly able to stimulate more
than five divisions of T-cells, indicative of a robust
immune response. Stimulation of DC with OK432
resulted in a marked up-regulation of the important
co-stimulatory marker CD40 on the surface of the DC,
compared to cytokine cocktail alone, which has not
been reported before with the 7 days DC generation
protocol. Engagement of CD40 on APC acts to license
T-cells and thereby recruiting additional DC and making
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Figure 5 DC matured with OK432 are exceeding the cytokine cocktail treated DC in allogeneic T-cell stimulation. DC were matured for
24 hours with the indicated stimuli, washed, irradiated, and 2×104 DC were co-cultured with 2×105CFSE labelled allogeneic leukocytes that had
the monocyte population removed, for 5 days. The cells were harvested, stained for CD4 and CD8, and analysed on a flowcytometer. Panel A
show the negligible effect the 0.1 KE OK432 compound has on the T-cell proliferation in an allogeneic leukocytes culture in the absence of
direct DC stimulation. Panel B shows the effect immature, cytokine cocktail and OK432 stimulated DC have on the total NK cell population (CD3-
CD16+CD56+/-) within an allogeneic leukocytes culture that had the monocyte population removed. Similar results were found using forty
thousand DC in the co-culture (data not shown). Histograms from one experiment are shown in C and D. Panel E and F show the median
percentage compared to cyto (from the same donor) set at 100 percent plus interquartile range in division number from 0 to 7, for CD4 and
CD8 positive cells. (n = 4). DC treated with OK432 induced more proliferation of both CD4 and CD8 positive cells and had a high proportion of
cells with the maximum detectable divisions. Figure key: Imm: Immature DC; Cyto: cytokine cocktail treated DC; OK432: 0.1KE OK432 treated DC.
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them more potent in eliciting an immune response [4].
The CD40 pathway indirectly amplifies the T-cell
response and thus is important in inducing a good cell
mediated immune response [26], which may also be
partly the reason why OK432 stimulated DC induced
such a high level of T-cell activation.
The ability to migrate towards CCL19 differed signifi-
cantly between the different stimuli. DC matured with
OK432 and cytokine cocktail had similar levels of CCR7
expression; OK432 treated DC did nevertheless migrate
less efficiently than DC treated with the cytokine cock-
tail. Sakakibara et al. [20] found OK432 DC to be better
at chemotaxis than the cytokine cocktail DC, but they
used less PGE2 in the cytokine cocktail than Jonuleit et
al. [11], which may account for the poorer migration of
the cytokine cocktail treated DC. PGE2 has been
demonstrated to be important for activating the migra-
tion machinery, independent of the level of CCR7 [34].
This also illustrates that the in vitro chemotaxis of DC
towards CCL19 is not determined solely by CCR7, but
also by additional mechanisms. Furthermore, it has been
suggested that a lower migration of DC could still be
sufficient if the DC that migrate in vivo were able to
induce a good T-cell response with a higher IL-12p70
production than the cytokine cocktail DC [43].
The ADP ribose hydroxylase CD38 has been reported
to be a novel marker for mature DC and involved in the
migratory capacity of DC [28,29,31] and we demon-
strated that OK432 up-regulated this marker. The corre-
lation analysis of all combined mature DC showed,
however, that the chemotaxis was clearly related to a
number of other maturation markers, particularly CD86
and CD83, whereas no significant correlation was found
to markers like CD38, or indeed, to CCR7. Furthermore,
CD38 expression seemed to be dependent on the
maturation stimuli, rather than the maturation status, as
CD38 was down-regulated on DC matured with the
cytokine cocktail. Other studies have shown that
increased migratory capacity was linked to increased
expression of CD38 on the surface of DC, but under
maturation conditions without PGE2 [28,31]. Conversely,
we found that OK432 treatment of DC up-regulated
both CD38 and CD83, but was still unable to induce
chemotaxis to the same extent as the cytokine cocktail.
Initiation of migration is a complex chain of events [44],
but at least the level of CD38 induced by the OK432
did not seem to be the critical determinant for the
induction of CCL19 directed chemotaxis.
Conclusions
As for the use of OK432 in cancer immunotherapy, we
have demonstrated that OK432 is better than the cytokine
cocktail in several critical aspects, i.e. IL-12p70 and IL-15
production, CD40 expression and T-cell stimulation.
It would therefore be interesting to verify if this could also
be beneficial when these DC are utilised in cancer immu-
notherapy. In conclusion, OK432 with its demonstrated
clinical efficacy and safety profile is an attractive com-
pound also in the context of DC based immunotherapy.
Additional material
Additional file 1: Table with MFI data. Median fluorescence intensities
(MFI) of markers shown in Figure 1.
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